Prenetics (PRE) CEO on Adding Crypto to Consumer Health

Prenetics (PRE) is “the world’s fastest growing consumer healthcare company” – and boasts a “sustainable Bitcoin Treasury.” CEO and cofounder Danny Yeung joined Market On Close to explain this dual strategy and his vision for the future. 

The company, founded in 2014, is based in Hong Kong. While it previously advertised itself as geared towards cancer prevention and treatment, now it is focused on “health and longevity.” They recently sold ACT Genomics, a personalized cancer treatment company, for $71.8 million.

Prenetics distributes supplements through IM8, which was cofounded by David Beckham. On its site, Prenetics says IM8 is on track to achieve $100 million in ARR within its first 12 months of operation. Besides that, it also owns CircleDNA, a DNA sequencing company, and Europa Sports Partners, which distributes sports nutrition.

IM8 is the flagship, with over 55,000 customers and over 4.9 million servings of its “Daily Ultimate Essentials” delivered in the first 6 months of its launch, according to Prenetics’ 1Q25 filing. It claims a 91% subscription rate and an average order value of $109. According to its site, IM8’s supplement products are developed by “experts from the Mayo Clinic and Nasa.”

The Bitcoin angle bets on continued crypto strength; the industry has seen growth and favorability under the Trump administration so far, but the sector remains volatile. Prenetics aims to hold $1B of Bitcoin within 5 years by strategically allocating capital on its balance sheet to it. 

Its “Bitcoin flywheel” takes cash flow from its healthcare business, invests it in Bitcoin, which it expects to strengthen its balance sheet and will allow it to make business investments and expand, and repeats from there. On its site, it currently says its holdings are around 377.5 Bitcoins. 

The company expects to reach profitability by 1Q26. In its latest report, 1Q25, it reported $17.3 million in revenue, a 170% increase from last year. Its consumer segment grew over 330%. It posted an adjusted EBITDA loss of $6.5 million from continuing operations. However, the company says it remains debt-free as of March 31, 2025.

In the report, Danny Yeung said, “Our strategic realignment towards the global consumer healthcare market is gaining tremendous traction.” He raised revenue expectations for the year and added that Prenetics has $78 million in cash and short-term assets. The stock is up over 150% year-to-date, even after a recent drop on Oct. 27 when it announced a $48 million equity offering.

Watch the full interview below:

Charles Schwab Media Productions Company and all third parties mentioned are separate and unaffiliated, and are not responsible for one another's policies, services or opinions.

Data contained herein is obtained from what are considered reliable sources. However, its accuracy, completeness, or reliability cannot be guaranteed. All events and times listed are subject to change without notice.